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Impact statement 
Death rattle is one of the most common symptoms in dying patients and therefore relevant to almost 
all health care settings worldwide. A recent literature review showed that there is no consensus 
regarding risk factors whose identification would facilitate early or prophylactic interventions. This 
research examined new potential risk factors besides previously investigated ones namely weight, 
smoking habits, final opioid and Midazolam doses and found that with increasing doses of Midazolam 
the likelihood of developing death rattle increases. This has the potential to directly impact clinical 
practice to replace Midazolam where possible and to be vigilant for timely intervention. 
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ABSTRACT 
 
Aim: Identification of risk factors predicting the development of death rattle 
 
Background: Respiratory tract secretions, often called death rattle, are among the 
most common symptoms in dying patients around the world. It is unknown whether 
death rattle causes distress in patients, but it has been globally reported that distress 
levels can be high in family members. Although there is a poor evidence base, 
treatment with antimuscarinic medication is standard practice worldwide and prompt 
intervention is recognised as crucial for effectiveness. The identification of risk 
factors for the development of death rattle would allow for targeted interventions. 
 
Design: A case  ̶control study was designed to retrospectively review two hundred 
consecutive medical records of mainly cancer patients who died in a hospice inpatient 
setting between 2009 and 2011. Fifteen potential risk factors including the original 
factors weight, smoking, final opioid dose and final Midazolam dose were 
investigated. 
 
Methods: Binary logistic regression to identify risk factors for death rattle 
development. 
 
Results: Univariate analysis showed death rattle was significantly associated with 
final Midazolam doses and final opioid doses, length of dying phase, and 
anticholinergic drug load in the pre-terminal phase. In the final logistic regression 
model only Midazolam was statistically significant, and only at final doses of 20 
mg/24hrs or over (OR 3.81 CI 1.41-10.34). 
 
Conclusions: Dying patients with a requirement for a high dose of Midazolam have an 
increased likelihood of developing death rattle. 
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Summary statement 
 
Why is this research or review needed? 
• In a systematic review and narrative analysis conducted by the authors no clear and 
undisputed risk factors were identified that predicted the development of death rattle 
in dying adults. 
• The identification of one or more risk factors predictive of death rattle development 
could lead to more targeted treatments and perhaps prophylaxis. 
 
What are the key findings? 
• Weight, smoking habits, final opioid doses and final Midazolam doses were 
investigated as potential risk factors for death rattle for the first time. Weight, 
smoking habits and final opioid doses were not found to be associated with the 
development of death rattle. 
• Midazolam given at the end of life increased the likelihood of death rattle, especially 
in dying adults who required increasing doses of Midazolam. 
 
How should the findings be used to influence policy/practice/research/education? 
• Clinicians should be mindful that dying adults with a higher dose requirement for 
Midazolam have an increased likelihood of developing death rattle. 
• Midazolam is commonly used in end-of-life care worldwide and future research 
should investigate the relationship between the development of death rattle and the 
administration of Midazolam.
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INTRODUCTION 
 
Death rattle is one of the most common symptoms in dying adults and predictive of 
impending death (Kehl & Kowalkowski, 2013). Death rattle has been defined as respiratory 
tract secretions that could not be cleared from oropharynx and trachea creating noisy 
('rattling') respiration as the secretions oscillate with expiration and inspiration (Twycross & 
Lichter 1999). Worldwide, off-label use of antimuscarinic medication is standard treatment 
for death rattle (Lindqvist et al. 2013). However, prompt intervention is crucial, as 
antimuscarinics reduce secretion production, but do not remove secretions that have already 
pooled in the airways (Back et al., 2001; Bennett et al., 2002). In addition, effectiveness of 
pharmacological treatments have been shown to be variable, making standardisation of 
treatment impossible which renders decision-making difficult for both prescribers and nurses 
who commonly administer these drugs  (Ahmedzai et al., 2015; Hirsch et al., 2012). It is 
unknown whether death rattle causes distress in patients, but distress levels can be high in 
family members (Shimizu et al. 2013). The identification of risk factors associated with the 
development of death rattle would allow for prophylactic treatments or at least enable early 
interventions (Kåss & Ellershaw, 2003; Sheehan et al., 2011; Wildiers et al., 2009). This 
article reports on a retrospective case ̶ control study that investigated potential risk factors 
associated with the development of death rattle in a dying adult. 
 
Background 
 
Risk factors associated with the development of death rattle have been investigated by a 
number of research groups, either as their main objective or in supplementary examinations of 
cohort characteristics (Bennett, 1996; Campbell & Yarandi, 2013; Clark et al., 2008; 
Ellershaw et al., 1995; Jakobsson et al., 2008; Kåss & Ellershaw, 2003; Morita et al., 2000, 
2004, 2005; Nakajima et al., 2013; Pace et al., 2009; Sheehan et al., 2011; Wildiers & 
Menten, 2002; Yamaguchi et al., 2012).
 
Many potential risk factors were identified in these 
studies, but there was no consensus regarding risk factors which may predict the development 
of death rattle in a dying adult. Table 1 illustrates the findings from these different researchers 
in chronological order which set the context for this current study. 
 
A systematic review was conducted to establish risk factors studied in relation to death rattle 
(Kolb et al., 2018). This paper describes the empirical investigation of the risk factors 
discovered in that review alongside other potential risk factors not previously examined. 
Table 2 itemises all the potential risk factors suitable for investigation in this study. It details 
whether these potential risk factors have already been investigated or if they are new and 
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identifies the literature on which the new risk factors are based. Potential risk factors that 
have not been investigated before are weight, smoking history, and doses of opioids and 
Midazolam. The rationale for their inclusion is explained next. 
 
Weight 
Anorexia is a common problem in dying cancer patients and can often result in considerable 
weight loss and cachexia (Morita et al., 2004; Mondello et al., 2015).
 
Alternatively, cancer 
modifying treatment, medication for symptom management and peripheral oedema can lead 
to substantial weight gain (Jakobsson et al., 2008; Schmitz, et al., 2014; Sturdza et al., 2008). 
It is known that obesity can cause pulmonary complications and worsen respiratory diseases 
(Koenig, 2001; Zammit et al., 2010). Therefore, weight was included as an original variable 
to be tested for association with death rattle. 
 
Smoking history 
Smoking is known to affect the respiratory system (Arcavi & Benowitz, 2004), and lung 
pathology was suggested to be a risk factor of death rattle (Kåss & Ellershaw, 2003). Kåss & 
Ellershaw (2003) recommended inclusion of a patient’s smoking history into future studies. 
They had found a significantly higher risk of death rattle in men and suggested that smoking 
might explain at least part of the association. Hence, smoking history was included as an 
original variable. 
 
Medications 
First line drug treatment for death rattle are antimuscarinic medications, such as Hyoscine 
hydrobromide, Hyoscine butylbromide or Glycopyrronium bromide, a subgroup of 
anticholinergic medications. They antagonise acetylcholine and thereby block 
parasympathetic activity leading to decreased production of airway secretions (Prommer 
2013). Other medications, especially medications given to the elderly and in palliative care, 
have anticholinergic properties causing side effects like dry mouth (Hoyle et al., 2012).  
 
The cumulative effect of one or more medications with anticholinergic properties is called 
anticholinergic load or burden (Fox et al. 2011). If medications given at the end of life 
contribute to the anticholinergic burden, then either they could provide protection from death 
rattle or, as Sheehan et al. (2011) found, might increase its risk. Although opioids and 
benzodiazepines in the form of Midazolam are only mildly anticholinergic, these are the 
medications most frequently given to patients at the end of life (Lindqvist et al., 2013). 
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Therefore, doses of these two medication groups on day of death were included as original 
potential risk factors. 
 
 
THE STUDY 
 
Aim 
 
The aim of the study was to identify risk factors that are associated with the development of 
death rattle in a dying adult. 
 
Design 
 
Retrospective case ̶ control study in which 200 medical records were reviewed. 
 
Participants 
 
A convenience sample of 200 consecutive medical records of patients who died in the 
inpatient unit of a hospice between 1 January 2009 and 2011 were selected for the study. 
Included were medical records of patients whose admission exceeded five days.  
 
The sample size was calculated according to MedCalc, a statistical software program 
(MedCalc,  n.d.) that suggests the following calculation of minimum sample size in logistic 
regression based on the work of Peduzzi et al. (1996): 
 
“Let p be the smallest of the proportions of negative or positive cases in the 
population and k the number of covariates (the number of independent variables), 
then the minimum number of cases to include is: N = 10 k / p.” 
 
This means for this research assuming 25% of patients do not develop DR: N=10k /0.25=40k. 
Therefore, a minimum of 40 cases was required for each independent variable entered in the 
logistic regression.  
 
Data collection 
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Data pertaining to the following potential risk factors associated with the development of 
death rattle were extracted from medical records and tabulated (see also Table 2): 
 
sex, age, weight, length of dying phase, length of stay, diagnosis, metastases, past medical 
history, fluid retention symptoms, smoking history, consciousness level, infection, regular 
opioid dose on day of death, regular Midazolam dose on day of death and anticholinergic load 
five days before death (pre-terminal phase). 
 
Table 3 shows the scale variables and the units in which they were measured, while Table 4 
displays the categorical variables with their respective categories. Based on the literature that 
implicated brain tumours because of their potential effect on the patient’s swallowing ability 
and diseases of the respiratory tract, the chosen categories for diagnosis and past medical 
history were illnesses potentially causing dysphagia, illnesses affecting breathing and other 
conditions. (Bennett, 1996; Ellershaw et al., 1995; Kåss & Ellershaw, 2003; Morita et al., 
2004, 2000). Utilising the opioid conversion chart for equianalgesia from Oxford Desk 
Reference/Oncology all opioid doses were converted to subcutaneous Morphine Sulphate so 
that a consistent scale variable could be created (Laird & Fallon, 2011). The anticholinergic 
load scores of medications prescribed five days before death were determined using the 
anticholinergic drug scale (ADS) as presented by Lertxundi et al. (2012) and total scores 
calculated. 
 
Drug dosages were grouped into categories given that association with death rattle will have 
been likely to be non-linear. Choice of cut-off points was largely arbitrary, aimed at both 
providing reasonable numbers in each group for analysis whilst also giving indication of low 
(or no), medium and high drug dosages. Box 1 and box 2 below show numbers included in 
these categories. 
 
Ethical considerations 
 
Ethical approval was granted for this research project from the studied hospice on 04.09.2015 
(Ref: SH/KB) and from the associated University on 22.10.2015 (Ref: CC/ESB).  
 
Data analysis 
 
First, a pre-selection process was carried out: univariate analyses were applied to all fifteen 
variables using Pearson’s chi-square (Table 5) and Mann-Whitney U tests (Table 6) to 
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determine associations between these variables and the outcome variable death rattle. Only 
variables that were statistically significant in this initial analysis became variables in the 
binary logistic regression analysis. The Statistical Package for the Social Sciences IBM SPSS 
Statistics 22 was used for data analysis. 
 
Validity, reliability and rigour 
 
A series of procedures were used to test the regression model regarding goodness-of-fit 
(Field, 2013). Besides the Hosmer and Lemeshaw goodness-of-fit test, Field (2013) and 
Pallant (2007) advise the examination of residuals to test how well the model fits regarding 
two aspects: firstly, which cases exert an undue influence on the model and secondly, for 
which cases the model does not fit. These residual tests were run with the logistic regression 
in SPSS. Finally, multi-collinearity diagnostics were performed. All test results confirmed a 
good model fit and absence of multi-collinearity. 
 
RESULTS 
 
The age range of the studied patients was 41 to 93 years with a mean of 72 years (SD 11.56). 
Sex was equally distributed with 47% male (n=94) and 53% female patients (n=106). Only 
4.5% (n=9) had a non-malignant diagnosis. In this sample, 75.5% developed death rattle 
while 24.5% did not. The results of the descriptive analyses of the data are included in Tables 
3 and 4.  
 
Table 7 shows the logistic regression models. The unadjusted odds ratios indicate that both 
final Midazolam and final opioid dose were associated with an increased likelihood of death 
rattle occurring when not adjusted. In the case of Midazolam, the increased odds were only 
statistically significant at the higher dosage. With a dose in the category of 20mg and over, 
Midazolam was associated with an increased likelihood of being associated with death rattle 
(OR 4.73 CI 1.84-12.19). A lower dosage of 1-19 mg/24 hrs had no statistically significant 
increase in odds to death rattle occurring. 
With regard to unadjusted analysis, and relative to those on doses of under 20 mg/24hrs of 
Morphine (or equianalgesic opioid) in the final day of life, those receiving a dosage of 20-99 
mg were nearly three times as likely to have experienced death rattle (OR 2.72 CI 1.20-6.17). 
An even higher likelihood was found for those who received a dose of 100+ mg of Morphine 
(OR3.25 CI 1.34-7.83).  
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With both drugs included in the model, the association between the final opioid dose and 
death rattle was no longer significant regardless of dosage. For Midazolam, higher doses 
remain statistically significant (OR 3.81 CI 1.405-10.336). 
 
DISCUSSION 
 
This study investigated whether there were any risk factors associated with the development 
of death rattle in a dying adult. Fifteen potential risk factors were isolated from 200 patients’ 
medical notes, some of which had not been researched before. Only variables that 
demonstrated a significance either in the Mann-Whitney U test or the Pearson’s Chi-square 
test were included in the regression analysis: length of dying phase, anticholinergic drug load 
on day five before death, final opioid dose, and final Midazolam dose. Only opioid and 
Midazolam doses were included in the regression model as the other variables did not 
contribute to the model.  
 
Midazolam was associated with death rattle at higher dosages. The apparent association 
between the final opioid dose and death rattle was confounded by the administration of 
Midazolam. With both drugs included in a single model, only Midazolam remained 
significant. Estimates suggested that the association between higher dosages of Midazolam 
and death rattle were high, with an odds ratio indicating those receiving the higher dosage to 
be more than three times as likely to experience a death rattle. However, despite the 
statistically significant results confidence intervals were wide given the relatively small 
numbers of people in the study and so estimates need to be treated with caution. 
 
Length of dying phase 
It has been suggested that a prolonged dying process might be associated with the 
development of death rattle (Kåss & Ellershaw, 2003). Duration of the dying process was 
assessed by researchers in different ways, either as length of stay (LOS) defined as survival 
time from admission to death or as duration of the terminal phase in hours. In this study LOS 
and terminal phase were both assessed. There was no association between LOS and death 
rattle found. The terminal phase was measured in days on an end-of-life pathway. Patients for 
whom this specific documentation was not used presumably died unexpectedly and fast. In 
these cases, length of dying phase was coded as zero days. Although length of dying phase 
was associated with death rattle according to the result of the Mann-Whitney-U test 
(p=0.013), it had no contributing value to the regression model and was excluded from it. 
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Two studies had previously investigated associations between LOS and death rattle and their 
findings contradicted each other (Bennett, 1996; Morita et al., 2000). Kåss & Ellershaw 
(2003) measured the terminal phase in hours on an end-of-life pathway (<4 hours; 4-24 hours; 
24-48 hours; 48-72 hours) and found that the risk of death rattle development increased with a 
prolonged dying phase. However, this study did not find that length of time in the dying phase 
could predict death rattle. 
 
Anticholinergic drug load 
Sheehan et al. (2011) tested the association between the anticholinergic drug score at the 
beginning of the deteriorating phase and the need for antimuscarinic drugs. Contrary to their 
expectations that a high anticholinergic drug load might provide protection for the patient 
regarding death rattle, they found a significant positive association between death rattle and 
anticholinergic drug load. They found that with each unit increase in the anticholinergic drug 
score (ADS) the likelihood of death rattle doubled. Sheehan et al.’s (2011) results could not 
be confirmed in this study, but both studies found that anticholinergic properties of 
medication were not protective of death rattle for the patients. 
 
Final opioid dose 
In the univariate analysis, final opioid dose was associated with death rattle. However, it was 
not statistically significant in the regression analysis. The variable was retained, however, as 
single predictor models do not take interactions between variables into account (Field, 2013). 
Residual testing confirmed that the model had four influential cases with extremely high 
opioid doses but particularly low Midazolam doses. If excluded this would have produced 
even stronger result for Midazolam as a predictor. 
 
Final Midazolam dose 
With increasing doses of Midazolam, the odds ratio associated with developing death rattle 
increased. This is an original finding, as Midazolam doses have not been investigated before 
as potential risk factors for death rattle. Midazolam can be used for different symptoms in 
end-of-life care, for breathlessness, agitation or delirium, as an anxiolytic sedative or as an 
anticonvulsant (HIS, 2014). It is prescribed in different doses depending on the indication. 
McNamara, et al. (1991) found that although the median dose was 30-35mg/24hrs of 
Midazolam for all indications, the range for muscle relaxation was 10-60mg/24hrs, for 
terminal agitated delirium 10-240mg/24hrs and for multifocal myoclonus or as prophylaxis 
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against seizures 15-80mg/24hrs. More recently, Masman et al. (2015) showed that the median 
dose had increased to 60mg/24hrs since their previous assessment.  
 
It is possible that Midazolam did not cause death rattle in these cases. Despite the dose 
dependent relationship, the statistical model used cannot attribute causality and therefore 
further research will be needed. Also, the final model only explained 11% variance. 
Nevertheless, it is plausible to consider Midazolam as a contributing factor. It is believed that 
death rattle is caused by the inability to clear secretion from the airways due to a reduced 
swallow and cough reflex (Bennett, 1996). It is reasonable to speculate that Midazolam would 
make this situation worse. Midazolam is a muscle relaxant and given in the terminal phase 
might result in the relaxation of the throat thereby further decreasing the ability to clear 
secretion that gathered (Back et al., 2001).
 
 
Limitations 
 
The retrospective nature of the study affected the quality of the data, particularly the 
measurement of weight, consciousness levels, smoking history and infection status. It also led 
to the exclusion of hydration levels at the outset as this was not recorded in the medical 
records. 
 
Further, doses of Midazolam and opioids were obtained from regular prescriptions. There is a 
possibility that results might have been different if ‘as required’ medication had been 
included. However, it was common practice in the study setting to include ‘as required’ 
medication from the previous 24 hours in the prescription of the continuous subcutaneous 
infusion for the next 24 hours. This meant that the data on Midazolam doses reflected 
precisely the previous 24 hours. As the day of death was of various lengths for individual 
patients the inclusion of prn medication from that time would have blurred the picture rather 
than increased the precision. 
 
Data was cross-sectional. It is very possible that those with a death rattle were more likely to 
receive Midazolam. It may be that health care professionals were more likely to perceive a 
person to be in distress if they had a death rattle. If so, then the association will reflect that 
concern, rather than the drug causing the rattle. That explanation is notable given implications 
for drug use in palliative care. Further research is clearly needed. 
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It could be argued that data from a prospective approach might have been of higher quality. 
However, as this study investigated a symptom that only occurs in the last days and hours of 
life, the cohort could be easily identified in a retrospective approach, including all patients 
who died in the studied time frame irrespective of their diagnosis or characteristics. This 
study could easily be replicated (Earle & Ayanian, 2006). 
 
The model only explained a little over 11% of the variance. Given that only two independent 
variables were included in the model, that is in itself a reasonably good fit. The other 89% of 
variance will likely have included factors relating to both the patient and those providing care. 
 
Finally, data collection was carried out in a hospice where most patients had a diagnosis of 
cancer and where very proactive symptom management was implemented. The 
generalisability to non-malignant diagnoses and other settings is not known. 
 
CONCLUSION 
 
This study investigated potential risk factors associated with the development of death rattle 
in adults at the end of life. It included analysis of risk factors that had not been investigated 
before. For the first time, medications given regularly in the terminal phase were investigated, 
and the Midazolam dose given on the last day of life was identified as a risk factor for the 
development of death rattle. This discovery is potentially important for practice and should be 
investigated further. 
 
Recommendations for practice 
 
Midazolam is a common medication used in in the last hours of life to treat a range of 
symptoms such as agitation, delirium or breathlessness (HIS, 2014). Scottish Palliative Care 
Guidelines (HIS, 2014) state that Midazolam should be titrated in 5 to 10mg steps. This study 
has shown that Midazolam dose was associated with the development of death rattle at higher 
doses. Medical and nursing professionals are advised to closely monitor patients who fall into 
this risk group, especially when doses of Midazolam increase as the patient approaches death. 
This study has shown the odds ratio associated with developing a death rattle was only 
statistically significant with doses over 20 mg where there was a nearly four-fold increase in 
the likelihood. This is a clinically relevant finding given 60mg was the median dose of 
Midazolam in Masman et al.'s study (2015).  
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It is recommended that pharmacological treatment of death rattle is started as soon as possible 
to enable this to be reduced (Bennett et al., 2002; Back et al., 2001). Prophylactic treatment 
for death rattle is not recommended in the British national palliative care guidelines 
(Ahmedzai et al., 2015), but has been discussed in the literature (Kåss & Ellershaw, 2003; 
Hugel et al., 2006; Bradley et al., 2010). Future research could investigate the feasibility of 
prophylactically treating patients who fall into a risk group or investigate alternative 
pharmacological management to replace Midazolam for some indication. 
 
Recommendations for future research 
 
Risk factors 
As highlighted in the limitations, some imprecision in the data became apparent during data 
collection. While these variables (i.e. weight, consciousness levels, smoking history and 
infection status) were non-significant in this study, the affected variables could be risk factors 
for death rattle if investigated in a future project with more accurate data. 
 
Prophylactic treatment  
Following the identification of a risk group new treatment options for death rattle should be 
considered. The feasibility of prophylactic treatment could be gauged in future research. 
 
Midazolam 
Logistic regression is unable to determine a causal relationship between an increased 
likelihood of developing death rattle with an increase of the Midazolam dose. Future research 
should utilise a different study design to explore why Midazolam is administered to individual 
patients and whether there is a causal connection between the development of death rattle and 
this medication at differing doses. Finally, should Midazolam be shown to have a relationship 
with death rattle, future research should explore the efficacy of other medications in the 
treatments of symptoms at the end of life. 
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Table 1. Risk factors investigated previously 
Author Year death rattle associated 
with 
death rattle not associated with 
Ellershaw et al. 1995 Primary lung cancer Hydration, infection 
 
Bennett 1996 Cerebral tumour, length of 
stay 
 
 
Morita et al.  2000 Lung, brain cancer, 
pulmonary pathology; 
Infection 
 
Sex, age, length of stay, 
consciousness level  
Wildier & 
Menten 
 
2002  Sex, age, diagnosis 
Kåss & 
Ellershaw 
 
2003 Primary lung cancer; male 
sex, prolonged deterioration 
 
Response to treatment not linked 
to pathology 
Morita et al.  2004 Primary lung cancer; 
dysphagia, infection 
Sex, age, metastases, brain 
tumour, pleural effusion, 
peripheral oedema 
 
Morita et al.  2005  Hydration 
 
Clark et al.  2008  Hydration 
 
Jakobsson et al.  2008 Disoriented patients Age, physical function 
 
Pace et al.  2009  Brain tumour 
 
Sheehan et al.  2011 Anticholinergic load Sex, age, diagnosis, metastases, 
past medical history, hydration 
 
Yamaguchi et al.  
 
2012  Hydration 
Nakajima et al. 2013 Hydration 
 
 
Campbell & 
Yarandi 
 
2013  Sex, age, ethnicity, diagnosis 
Likar et al. 2016 female sex 
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Table 3. Descriptive statistics of scale variables 
 
variable (unit) Range mean median mode SD 
age (years) 52 (41-93) 72 74 76 11.56 
length of dying 
phase (days) 
10 (0-10) 2 2 2 1.83 
LOS (days) 275 (6-281) 28  19 6 35 
Midazolam (mg) 100 (0-100) 20.86 15 0 22.3 
Morphine (mg) 2250 (0-2250) 166.92 50.5 20 339.82 
 
LOS= length of stay (length of admission); mg= milligrams (as injection); SD= standard deviation 
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Table 4. Descriptive statistics of categorical variables 
variable categories N % 
death rattle (outcome 
variable) 
present 151 75.5 
 absent 49 24.5 
sex 
 
diagnosis 
 
 
metastases 
 
 
 
past medical history 
 
 
 
fluid retention symptoms 
male 
female 
affecting breathing 
affecting swallow 
other 
none 
lung 
brain 
other 
none 
affecting breathing 
affecting swallow 
other 
absent 
94 
106 
43 
31 
126 
54 
29 
15 
102 
33 
37 
25 
105 
101 
47 
53 
21.5 
15.5 
63 
27 
14.5 
7.5 
51 
16.5 
18.5 
12.5 
52.5 
52.1 
 peripheral oedema 73 37.6 
 ascites/ pleural effusion 12 6.2 
 both 8 4.1 
consciousness conscious 9 4.7 
 semi-conscious 19 9.9 
 unconscious 164 85.4 
smoking non-smoker 80 44.4 
 ex-smoker 64 35.6 
 smoker 36 20 
infection absent 146 73 
 chest 22 11 
 other/unknown site 31 15.5 
Anticholinergic drug score 
 
<2 
2-3 
31 
101 
15.5 
50.5 
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variable categories N % 
 
weight 
>3 
below average 
68 
56 
34 
33.7 
 average 87 52.4 
 above average 23 13.9 
 
Midazolam dose† none 35 17.5 
 1-19 mg 82 41.0 
 
 
20 mg+ 81 41.5 
Morphine dose† 
 
0-19 mg 
20-99 mg 
100 mg+ 
38 
90 
71 
19.0 
45.0 
35.5 
† categories in regression model 
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Table 5. Pearson’s Chi-square test for categorical variables 
 
Variable Chi-square p-value 
sex χ
2
(1, N=200) = 0.655 p = 0.418 
weight χ
2
(2, N=166) = 3.278 p = 0.194 
diagnosis χ
2
(2, N=200) = 3.269 p = 0.195 
metastases χ
2
(3, N=200) = 4.213 p = 0.239 
past medical history χ
2
(3, N=200) = 3.054 p = 0.383 
smoking χ
2
(2, N=180) = 2.021 p = 0.364 
consciousness χ
2
(2, N=192) = 2.095 p = 0.351 
infection 
oedema 
χ
2
(2, N=199) = 0.873 
χ
2
(3, N=194) = 6.291 
p = 0.646 
p = 0.098 
anticholinergic load χ
2
(2, N=200) = 6.628 p = 0.036* 
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Table 6.  Mann-Whitney U test statistics of scale variables 
 
 Length of dying 
phase 
Opioid Midazolam 
U 4.496 4.486 4.7815 
z 2.472 2.481 3.442 
p 0.013* 0.013* 0.001* 
 
U= Mann-Whitney U; z= standardised test statistic; p= significance value 
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Table 7. Logistic Regression Models 
                  
    Unadjusted       Adjusted
1
     
Drug 
Dosage 
(mg) Odds Ratio 
95% Confidence 
Interval   
Odds 
Ratio 
95% Confidence 
Interval 
      Lower Upper     Lower Upper 
Midazolam 0 Comparison   Comparison 
  1-19 1.61 0.71 3.68   1.56 0.68 3.62 
  20+ 4.73 1.84 12.19   3.81 1.41 10.34 
                  
Morphine 0-19 Comparison   Comparison 
  20-99 2.72 1.20 6.17   1.88 0.80 4.44 
  100+ 3.25 1.34 7.83   1.90 0.72 5.00 
1
 Nagelkerke r
2
 = 0.11 
  
              

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Box 1. Midazolam categories 
Midazolam     
Dosage n % 
0 35 17.5 
1-19 82 41.0 
20-39 81 40.5 
Missing 2 1.0 
Total 200 100 
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Morpine     
Dosage n % 
0-19 38 19.0 
20-99 90 45.0 
100+ 71 35.5 
Missing 1 0.5 
Total 200 100 
      
Box 2. Morphine categories 
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